Abstract GS03-03: Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial

医学 芳香化酶抑制剂 肿瘤科 乳腺癌 内科学 非甾体 癌症 佐剂 芳香化酶
作者
Gabriel N. Hortobágyi,Daniil L. Stroyakovsky,Denise Aysel Yardley,Chiun‐Sheng Huang,Peter Andreas Fasching,John Paul Crown,Aditya Bardia,Stephen Chia,Seock‐Ah Im,Miguel Martín,Sherene Loi,Binghe Xu,Sara Alsterlind Hurvitz,Carlos H. Barrios,Michael Untch,Rebecca Moroose,Frances M. Visco,Federico Parnizari,Farhat Ghaznawi,Zheng Li
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (9_Supplement): GS03-03 被引量:11
标识
DOI:10.1158/1538-7445.sabcs23-gs03-03
摘要

Abstract Background: Interim results from the phase 3 NATALEE trial demonstrated that adding RIB to standard-of-care adjuvant NSAI had a statistically significant iDFS benefit in patients with stage II and III HR+/HER2− early breast cancer at risk of recurrence, including those with node-negative disease (Slamon et al, ASCO 2023). We present the final protocol-specified analysis of the primary endpoint of iDFS. Methods: A total of 5101 pre-/postmenopausal women and men underwent 1:1 randomization to receive RIB (400 mg/day; 3 weeks on/1 week off for 36 months) + NSAI (letrozole 2.5 mg/day or anastrozole 1 mg/day for ≥60 months) or NSAI alone. Men and premenopausal women received goserelin (3.6 mg once every 28 days). Patients were required to have anatomic stage IIA (either N0 with additional risk factors or N1), IIB, or III breast cancer per the AJCC (8th edition). Patients remained on trial as long as they were continuing on NSAI (≤5 years), regardless of RIB discontinuation. The primary endpoint was iDFS according to STEEP v1.0 criteria, and the secondary efficacy endpoints were recurrence-free survival (RFS), distant disease–free survival (DDFS), and overall survival (OS). This final analysis was planned after approximately 500 iDFS events. iDFS was evaluated by the Kaplan-Meier method, and statistical comparison was made by a stratified log-rank test. P values were not corrected for multiple comparisons. Results: At the data cutoff (July 21, 2023), among the 2549 patients in the RIB + NSAI arm, 1091 (42.8%) completed 3 years of RIB treatment, and 905 (35.5%) discontinued RIB or RIB + NSAI early and 528 patients (20.7%) remained on RIB. 1748 patients (68.5%) remain on treatment in the NSAI arm. Median follow-up for iDFS was 33.3 months, an additional 5.6 months from the previous interim analysis. A total of 509 iDFS events were observed, 226 (8.9%) in the RIB + NSAI arm and 283 (11.1%) in the NSAI alone arm. RIB + NSAI demonstrated a significant iDFS benefit over NSAI alone (HR, 0.749; 95% CI, 0.628-0.892; P=.0006). The 3-year iDFS rates were 90.7% (95% CI, 89.3%-91.8%) vs 87.6% (95% CI, 86.1%-88.9%). A consistent benefit was observed across patient subgroups, including those with node-negative, stage II, or stage III disease (Table). Secondary endpoints of DDFS and RFS favored RIB + NSAI over NSAI alone (Table). OS data were immature, with 84 (3.3%) and 88 (3.4%) total events in the RIB + NSAI and NSAI alone arms, respectively. No new safety signals were observed since the prior interim analysis. Discontinuation of RIB due to adverse events was observed in 19.5% of patients (a <1% increase from the prior interim analysis). Conclusions: With a substantial proportion of patients completing 3 years of RIB treatment, NATALEE continues to demonstrate a significant iDFS improvement with RIB + NSAI over NSAI alone. Efficacy results confirm continued improvement in benefit across subgroups, including stage II disease. Safety findings support the manageable toxicity profile of RIB at the 400-mg starting dose in early breast cancer. Table. Citation Format: Gabriel Hortobagyi, Daniil Stroyakovsky, Denise Yardley, Chiun-Shen Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock-Ah Im, Miguel Martín, Sherene Loi, Binghe Xu, Sara Hurvitz, Carlos Barrios, Michael Untch, Rebecca Moroose, Frances Visco, Federico Parnizari, Farhat Ghaznawi, Zheng Li, Sorcha Waters, Arunava Chakravartty, Dennis Slamon. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr GS03-03.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
云淡风清完成签到 ,获得积分0
刚刚
1秒前
1秒前
gloria发布了新的文献求助10
1秒前
星辰大海的应助被cjxlllll采纳,获得10
1秒前
温暖砖头发布了新的文献求助10
1秒前
杰克李李发布了新的文献求助10
2秒前
2秒前
3秒前
4秒前
星辰大海的应助被淡然的宛秋采纳,获得10
5秒前
5秒前
万能图书馆的应助被衣美竹采纳,获得10
6秒前
UPC_ZZM完成签到,获得积分10
6秒前
6秒前
小懒完成签到,获得积分10
7秒前
WZH完成签到,获得积分10
8秒前
8秒前
传奇3的应助被ay采纳,获得10
8秒前
skper发布了新的文献求助10
9秒前
9秒前
9秒前
小二郎的应助被niko采纳,获得10
9秒前
tomatoGG发布了新的文献求助10
9秒前
10秒前
llllllll关注了科研通微信公众号
11秒前
zhangzhen发布了新的文献求助10
11秒前
11秒前
mm的应助被甜甜天德采纳,获得10
11秒前
11秒前
11秒前
wmz完成签到,获得积分10
12秒前
梦寐寤寐发布了新的文献求助10
12秒前
13秒前
丘比特的应助被温暖砖头采纳,获得10
13秒前
13秒前
13秒前
斯文败类的应助被逆流而上采纳,获得10
14秒前
时尚的诗珊完成签到,获得积分10
15秒前
秋风的应助被徐枘采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193335
求助须知:如何正确求助?哪些是违规求助? 9579489
关于积分的说明 21865844
捐赠科研通 7792843
什么是DOI,文献DOI怎么找? 3437210
关于科研通互助平台的介绍 2560687
邀请新用户注册赠送积分活动 2483996